nodes	percent_of_prediction	percent_of_DWPC	metapath
Sparfloxacin—TOP2A—Teniposide—lymphatic system cancer	0.366	0.452	CbGbCtD
Sparfloxacin—TOP2A—Mitoxantrone—lymphatic system cancer	0.256	0.316	CbGbCtD
Sparfloxacin—ABCC2—Vincristine—lymphatic system cancer	0.0723	0.0892	CbGbCtD
Sparfloxacin—ABCC2—Methotrexate—lymphatic system cancer	0.0438	0.054	CbGbCtD
Sparfloxacin—ABCB1—Mitoxantrone—lymphatic system cancer	0.0342	0.0423	CbGbCtD
Sparfloxacin—ABCB1—Vincristine—lymphatic system cancer	0.0236	0.0291	CbGbCtD
Sparfloxacin—ABCB1—Methotrexate—lymphatic system cancer	0.0143	0.0176	CbGbCtD
Sparfloxacin—TOP2A—Etoposide—Teniposide—lymphatic system cancer	0.00127	0.195	CbGdCrCtD
Sparfloxacin—TOP2A—Podofilox—Teniposide—lymphatic system cancer	0.000971	0.149	CbGdCrCtD
Sparfloxacin—TOP2A—Vindesine—Vincristine—lymphatic system cancer	0.000916	0.14	CbGdCrCtD
Sparfloxacin—TOP2A—Vinorelbine—Vincristine—lymphatic system cancer	0.000578	0.0884	CbGdCrCtD
Sparfloxacin—TOP2A—Cladribine—Fludarabine—lymphatic system cancer	0.000437	0.0669	CbGdCrCtD
Sparfloxacin—TOP2A—Clofarabine—Fludarabine—lymphatic system cancer	0.000404	0.0618	CbGdCrCtD
Sparfloxacin—TOP2A—Vinblastine—Vincristine—lymphatic system cancer	0.000397	0.0608	CbGdCrCtD
Sparfloxacin—TOP2A—Clofarabine—Cytarabine—lymphatic system cancer	0.000382	0.0584	CbGdCrCtD
Sparfloxacin—Body temperature increased—Teniposide—lymphatic system cancer	0.000365	0.00199	CcSEcCtD
Sparfloxacin—Abdominal pain—Teniposide—lymphatic system cancer	0.000365	0.00199	CcSEcCtD
Sparfloxacin—Paraesthesia—Fludarabine—lymphatic system cancer	0.000364	0.00198	CcSEcCtD
Sparfloxacin—Hallucination—Carmustine—lymphatic system cancer	0.000364	0.00198	CcSEcCtD
Sparfloxacin—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000364	0.00198	CcSEcCtD
Sparfloxacin—Sweating—Mitoxantrone—lymphatic system cancer	0.000363	0.00197	CcSEcCtD
Sparfloxacin—Dyspnoea—Fludarabine—lymphatic system cancer	0.000362	0.00197	CcSEcCtD
Sparfloxacin—Haematuria—Mitoxantrone—lymphatic system cancer	0.000361	0.00196	CcSEcCtD
Sparfloxacin—Oedema peripheral—Carmustine—lymphatic system cancer	0.00036	0.00196	CcSEcCtD
Sparfloxacin—Dyspepsia—Fludarabine—lymphatic system cancer	0.000357	0.00194	CcSEcCtD
Sparfloxacin—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000355	0.00193	CcSEcCtD
Sparfloxacin—TOP2A—Gemcitabine—Cytarabine—lymphatic system cancer	0.000354	0.0541	CbGdCrCtD
Sparfloxacin—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000353	0.00192	CcSEcCtD
Sparfloxacin—Decreased appetite—Fludarabine—lymphatic system cancer	0.000353	0.00192	CcSEcCtD
Sparfloxacin—Hallucination—Vincristine—lymphatic system cancer	0.000347	0.00189	CcSEcCtD
Sparfloxacin—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000347	0.00189	CcSEcCtD
Sparfloxacin—Pain—Fludarabine—lymphatic system cancer	0.000347	0.00189	CcSEcCtD
Sparfloxacin—Constipation—Fludarabine—lymphatic system cancer	0.000347	0.00189	CcSEcCtD
Sparfloxacin—Vasculitis—Methotrexate—lymphatic system cancer	0.000345	0.00188	CcSEcCtD
Sparfloxacin—TOP2A—Cytarabine—Fludarabine—lymphatic system cancer	0.000344	0.0526	CbGdCrCtD
Sparfloxacin—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000341	0.00186	CcSEcCtD
Sparfloxacin—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000341	0.00185	CcSEcCtD
Sparfloxacin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00034	0.00185	CcSEcCtD
Sparfloxacin—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00034	0.00185	CcSEcCtD
Sparfloxacin—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00034	0.00185	CcSEcCtD
Sparfloxacin—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000338	0.00184	CcSEcCtD
Sparfloxacin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000337	0.00183	CcSEcCtD
Sparfloxacin—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.000337	0.00183	CcSEcCtD
Sparfloxacin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000334	0.00182	CcSEcCtD
Sparfloxacin—Asthenia—Teniposide—lymphatic system cancer	0.000331	0.0018	CcSEcCtD
Sparfloxacin—Malaise—Bleomycin—lymphatic system cancer	0.000329	0.00179	CcSEcCtD
Sparfloxacin—Pruritus—Teniposide—lymphatic system cancer	0.000327	0.00178	CcSEcCtD
Sparfloxacin—Arrhythmia—Carmustine—lymphatic system cancer	0.000326	0.00178	CcSEcCtD
Sparfloxacin—Alopecia—Carmustine—lymphatic system cancer	0.000323	0.00176	CcSEcCtD
Sparfloxacin—Body temperature increased—Fludarabine—lymphatic system cancer	0.000321	0.00174	CcSEcCtD
Sparfloxacin—Vaginal infection—Methotrexate—lymphatic system cancer	0.000318	0.00173	CcSEcCtD
Sparfloxacin—Cough—Bleomycin—lymphatic system cancer	0.000318	0.00173	CcSEcCtD
Sparfloxacin—Diarrhoea—Teniposide—lymphatic system cancer	0.000316	0.00172	CcSEcCtD
Sparfloxacin—Chest pain—Bleomycin—lymphatic system cancer	0.00031	0.00169	CcSEcCtD
Sparfloxacin—Myalgia—Bleomycin—lymphatic system cancer	0.00031	0.00169	CcSEcCtD
Sparfloxacin—Alopecia—Vincristine—lymphatic system cancer	0.000308	0.00168	CcSEcCtD
Sparfloxacin—Back pain—Carmustine—lymphatic system cancer	0.000308	0.00167	CcSEcCtD
Sparfloxacin—Discomfort—Bleomycin—lymphatic system cancer	0.000307	0.00167	CcSEcCtD
Sparfloxacin—Chills—Mitoxantrone—lymphatic system cancer	0.000305	0.00166	CcSEcCtD
Sparfloxacin—Urine output increased—Methotrexate—lymphatic system cancer	0.000305	0.00166	CcSEcCtD
Sparfloxacin—Ecchymosis—Methotrexate—lymphatic system cancer	0.000305	0.00166	CcSEcCtD
Sparfloxacin—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000305	0.00166	CcSEcCtD
Sparfloxacin—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000303	0.00165	CcSEcCtD
Sparfloxacin—Alopecia—Mitoxantrone—lymphatic system cancer	0.0003	0.00163	CcSEcCtD
Sparfloxacin—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.0003	0.00163	CcSEcCtD
Sparfloxacin—Confusional state—Bleomycin—lymphatic system cancer	0.0003	0.00163	CcSEcCtD
Sparfloxacin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000299	0.00163	CcSEcCtD
Sparfloxacin—Tremor—Carmustine—lymphatic system cancer	0.000298	0.00162	CcSEcCtD
Sparfloxacin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000297	0.00162	CcSEcCtD
Sparfloxacin—Back pain—Vincristine—lymphatic system cancer	0.000294	0.0016	CcSEcCtD
Sparfloxacin—Vomiting—Teniposide—lymphatic system cancer	0.000293	0.0016	CcSEcCtD
Sparfloxacin—Agitation—Carmustine—lymphatic system cancer	0.000292	0.00159	CcSEcCtD
Sparfloxacin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000291	0.00158	CcSEcCtD
Sparfloxacin—Asthenia—Fludarabine—lymphatic system cancer	0.000291	0.00158	CcSEcCtD
Sparfloxacin—Rash—Teniposide—lymphatic system cancer	0.000291	0.00158	CcSEcCtD
Sparfloxacin—Dermatitis—Teniposide—lymphatic system cancer	0.000291	0.00158	CcSEcCtD
Sparfloxacin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00029	0.00158	CcSEcCtD
Sparfloxacin—Headache—Teniposide—lymphatic system cancer	0.000289	0.00157	CcSEcCtD
Sparfloxacin—Pruritus—Fludarabine—lymphatic system cancer	0.000287	0.00156	CcSEcCtD
Sparfloxacin—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000287	0.00156	CcSEcCtD
Sparfloxacin—Back pain—Mitoxantrone—lymphatic system cancer	0.000286	0.00156	CcSEcCtD
Sparfloxacin—Anorexia—Bleomycin—lymphatic system cancer	0.000284	0.00154	CcSEcCtD
Sparfloxacin—Agitation—Vincristine—lymphatic system cancer	0.000279	0.00152	CcSEcCtD
Sparfloxacin—Polyuria—Methotrexate—lymphatic system cancer	0.000279	0.00152	CcSEcCtD
Sparfloxacin—Diarrhoea—Fludarabine—lymphatic system cancer	0.000278	0.00151	CcSEcCtD
Sparfloxacin—Convulsion—Carmustine—lymphatic system cancer	0.000276	0.0015	CcSEcCtD
Sparfloxacin—Hypertension—Carmustine—lymphatic system cancer	0.000275	0.00149	CcSEcCtD
Sparfloxacin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000274	0.00149	CcSEcCtD
Sparfloxacin—Nausea—Teniposide—lymphatic system cancer	0.000274	0.00149	CcSEcCtD
Sparfloxacin—Vertigo—Vincristine—lymphatic system cancer	0.000273	0.00148	CcSEcCtD
Sparfloxacin—Hepatic failure—Methotrexate—lymphatic system cancer	0.000272	0.00148	CcSEcCtD
Sparfloxacin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000271	0.00147	CcSEcCtD
Sparfloxacin—Chest pain—Carmustine—lymphatic system cancer	0.000271	0.00147	CcSEcCtD
Sparfloxacin—Myalgia—Carmustine—lymphatic system cancer	0.000271	0.00147	CcSEcCtD
Sparfloxacin—Anxiety—Carmustine—lymphatic system cancer	0.00027	0.00147	CcSEcCtD
Sparfloxacin—Paraesthesia—Bleomycin—lymphatic system cancer	0.000267	0.00145	CcSEcCtD
Sparfloxacin—Malaise—Mitoxantrone—lymphatic system cancer	0.000267	0.00145	CcSEcCtD
Sparfloxacin—Dyspnoea—Bleomycin—lymphatic system cancer	0.000265	0.00144	CcSEcCtD
Sparfloxacin—Renal failure acute—Methotrexate—lymphatic system cancer	0.000265	0.00144	CcSEcCtD
Sparfloxacin—Convulsion—Vincristine—lymphatic system cancer	0.000263	0.00143	CcSEcCtD
Sparfloxacin—Hypertension—Vincristine—lymphatic system cancer	0.000262	0.00143	CcSEcCtD
Sparfloxacin—Confusional state—Carmustine—lymphatic system cancer	0.000262	0.00142	CcSEcCtD
Sparfloxacin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000259	0.00141	CcSEcCtD
Sparfloxacin—Decreased appetite—Bleomycin—lymphatic system cancer	0.000259	0.00141	CcSEcCtD
Sparfloxacin—Myalgia—Vincristine—lymphatic system cancer	0.000259	0.00141	CcSEcCtD
Sparfloxacin—Cough—Mitoxantrone—lymphatic system cancer	0.000258	0.0014	CcSEcCtD
Sparfloxacin—Vomiting—Fludarabine—lymphatic system cancer	0.000258	0.0014	CcSEcCtD
Sparfloxacin—Convulsion—Mitoxantrone—lymphatic system cancer	0.000256	0.00139	CcSEcCtD
Sparfloxacin—Rash—Fludarabine—lymphatic system cancer	0.000256	0.00139	CcSEcCtD
Sparfloxacin—Dermatitis—Fludarabine—lymphatic system cancer	0.000256	0.00139	CcSEcCtD
Sparfloxacin—Hypertension—Mitoxantrone—lymphatic system cancer	0.000255	0.00139	CcSEcCtD
Sparfloxacin—Pain—Bleomycin—lymphatic system cancer	0.000254	0.00138	CcSEcCtD
Sparfloxacin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000254	0.00138	CcSEcCtD
Sparfloxacin—Headache—Fludarabine—lymphatic system cancer	0.000254	0.00138	CcSEcCtD
Sparfloxacin—Tachycardia—Carmustine—lymphatic system cancer	0.000253	0.00138	CcSEcCtD
Sparfloxacin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000253	0.00138	CcSEcCtD
Sparfloxacin—Myalgia—Mitoxantrone—lymphatic system cancer	0.000252	0.00137	CcSEcCtD
Sparfloxacin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000252	0.00137	CcSEcCtD
Sparfloxacin—Chest pain—Mitoxantrone—lymphatic system cancer	0.000252	0.00137	CcSEcCtD
Sparfloxacin—Anxiety—Mitoxantrone—lymphatic system cancer	0.000251	0.00137	CcSEcCtD
Sparfloxacin—Discomfort—Mitoxantrone—lymphatic system cancer	0.000249	0.00135	CcSEcCtD
Sparfloxacin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000248	0.00135	CcSEcCtD
Sparfloxacin—Anorexia—Carmustine—lymphatic system cancer	0.000247	0.00135	CcSEcCtD
Sparfloxacin—TOP2A—Azacitidine—Fludarabine—lymphatic system cancer	0.000247	0.0377	CbGdCrCtD
Sparfloxacin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000245	0.00133	CcSEcCtD
Sparfloxacin—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000245	0.00133	CcSEcCtD
Sparfloxacin—Confusional state—Mitoxantrone—lymphatic system cancer	0.000243	0.00132	CcSEcCtD
Sparfloxacin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000243	0.00132	CcSEcCtD
Sparfloxacin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000241	0.00131	CcSEcCtD
Sparfloxacin—Nausea—Fludarabine—lymphatic system cancer	0.000241	0.00131	CcSEcCtD
Sparfloxacin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00024	0.0013	CcSEcCtD
Sparfloxacin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000237	0.00129	CcSEcCtD
Sparfloxacin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000236	0.00129	CcSEcCtD
Sparfloxacin—Urticaria—Bleomycin—lymphatic system cancer	0.000236	0.00129	CcSEcCtD
Sparfloxacin—Anorexia—Vincristine—lymphatic system cancer	0.000236	0.00129	CcSEcCtD
Sparfloxacin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000236	0.00128	CcSEcCtD
Sparfloxacin—Body temperature increased—Bleomycin—lymphatic system cancer	0.000235	0.00128	CcSEcCtD
Sparfloxacin—Insomnia—Carmustine—lymphatic system cancer	0.000235	0.00128	CcSEcCtD
Sparfloxacin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000233	0.00127	CcSEcCtD
Sparfloxacin—Paraesthesia—Carmustine—lymphatic system cancer	0.000233	0.00127	CcSEcCtD
Sparfloxacin—TOP2A—Azacitidine—Cytarabine—lymphatic system cancer	0.000233	0.0356	CbGdCrCtD
Sparfloxacin—Mood swings—Methotrexate—lymphatic system cancer	0.000232	0.00126	CcSEcCtD
Sparfloxacin—Dyspnoea—Carmustine—lymphatic system cancer	0.000231	0.00126	CcSEcCtD
Sparfloxacin—Somnolence—Carmustine—lymphatic system cancer	0.000231	0.00126	CcSEcCtD
Sparfloxacin—Anorexia—Mitoxantrone—lymphatic system cancer	0.00023	0.00125	CcSEcCtD
Sparfloxacin—Ataxia—Methotrexate—lymphatic system cancer	0.00023	0.00125	CcSEcCtD
Sparfloxacin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000226	0.00123	CcSEcCtD
Sparfloxacin—Decreased appetite—Carmustine—lymphatic system cancer	0.000226	0.00123	CcSEcCtD
Sparfloxacin—Insomnia—Vincristine—lymphatic system cancer	0.000224	0.00122	CcSEcCtD
Sparfloxacin—Paraesthesia—Vincristine—lymphatic system cancer	0.000223	0.00121	CcSEcCtD
Sparfloxacin—Constipation—Carmustine—lymphatic system cancer	0.000222	0.00121	CcSEcCtD
Sparfloxacin—Pain—Carmustine—lymphatic system cancer	0.000222	0.00121	CcSEcCtD
Sparfloxacin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00022	0.0012	CcSEcCtD
Sparfloxacin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00022	0.0012	CcSEcCtD
Sparfloxacin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000219	0.00119	CcSEcCtD
Sparfloxacin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000217	0.00118	CcSEcCtD
Sparfloxacin—Decreased appetite—Vincristine—lymphatic system cancer	0.000215	0.00117	CcSEcCtD
Sparfloxacin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000215	0.00117	CcSEcCtD
Sparfloxacin—Somnolence—Mitoxantrone—lymphatic system cancer	0.000215	0.00117	CcSEcCtD
Sparfloxacin—Feeling abnormal—Carmustine—lymphatic system cancer	0.000214	0.00116	CcSEcCtD
Sparfloxacin—Asthenia—Bleomycin—lymphatic system cancer	0.000213	0.00116	CcSEcCtD
Sparfloxacin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000212	0.00116	CcSEcCtD
Sparfloxacin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000212	0.00116	CcSEcCtD
Sparfloxacin—Pain—Vincristine—lymphatic system cancer	0.000212	0.00115	CcSEcCtD
Sparfloxacin—Constipation—Vincristine—lymphatic system cancer	0.000212	0.00115	CcSEcCtD
Sparfloxacin—Asthma—Methotrexate—lymphatic system cancer	0.000211	0.00115	CcSEcCtD
Sparfloxacin—Pruritus—Bleomycin—lymphatic system cancer	0.00021	0.00115	CcSEcCtD
Sparfloxacin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00021	0.00114	CcSEcCtD
Sparfloxacin—Pancreatitis—Methotrexate—lymphatic system cancer	0.000207	0.00113	CcSEcCtD
Sparfloxacin—Pain—Mitoxantrone—lymphatic system cancer	0.000206	0.00112	CcSEcCtD
Sparfloxacin—Constipation—Mitoxantrone—lymphatic system cancer	0.000206	0.00112	CcSEcCtD
Sparfloxacin—Abdominal pain—Carmustine—lymphatic system cancer	0.000205	0.00112	CcSEcCtD
Sparfloxacin—Body temperature increased—Carmustine—lymphatic system cancer	0.000205	0.00112	CcSEcCtD
Sparfloxacin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000203	0.0011	CcSEcCtD
Sparfloxacin—Pancytopenia—Methotrexate—lymphatic system cancer	0.000201	0.00109	CcSEcCtD
Sparfloxacin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000199	0.00108	CcSEcCtD
Sparfloxacin—Dysuria—Methotrexate—lymphatic system cancer	0.000198	0.00108	CcSEcCtD
Sparfloxacin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000197	0.00107	CcSEcCtD
Sparfloxacin—Body temperature increased—Vincristine—lymphatic system cancer	0.000196	0.00107	CcSEcCtD
Sparfloxacin—Abdominal pain—Vincristine—lymphatic system cancer	0.000196	0.00107	CcSEcCtD
Sparfloxacin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000193	0.00105	CcSEcCtD
Sparfloxacin—Urticaria—Mitoxantrone—lymphatic system cancer	0.000192	0.00104	CcSEcCtD
Sparfloxacin—Hypersensitivity—Carmustine—lymphatic system cancer	0.000191	0.00104	CcSEcCtD
Sparfloxacin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000191	0.00104	CcSEcCtD
Sparfloxacin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000191	0.00104	CcSEcCtD
Sparfloxacin—Pneumonia—Methotrexate—lymphatic system cancer	0.00019	0.00103	CcSEcCtD
Sparfloxacin—Vomiting—Bleomycin—lymphatic system cancer	0.000189	0.00103	CcSEcCtD
Sparfloxacin—Rash—Bleomycin—lymphatic system cancer	0.000188	0.00102	CcSEcCtD
Sparfloxacin—Dermatitis—Bleomycin—lymphatic system cancer	0.000187	0.00102	CcSEcCtD
Sparfloxacin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000187	0.00102	CcSEcCtD
Sparfloxacin—Asthenia—Carmustine—lymphatic system cancer	0.000186	0.00101	CcSEcCtD
Sparfloxacin—Stomatitis—Methotrexate—lymphatic system cancer	0.000184	0.001	CcSEcCtD
Sparfloxacin—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000183	0.000997	CcSEcCtD
Sparfloxacin—Hypersensitivity—Vincristine—lymphatic system cancer	0.000183	0.000994	CcSEcCtD
Sparfloxacin—Sweating—Methotrexate—lymphatic system cancer	0.000181	0.000984	CcSEcCtD
Sparfloxacin—Haematuria—Methotrexate—lymphatic system cancer	0.00018	0.000978	CcSEcCtD
Sparfloxacin—Epistaxis—Methotrexate—lymphatic system cancer	0.000178	0.000968	CcSEcCtD
Sparfloxacin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000178	0.000968	CcSEcCtD
Sparfloxacin—Asthenia—Vincristine—lymphatic system cancer	0.000178	0.000968	CcSEcCtD
Sparfloxacin—Diarrhoea—Carmustine—lymphatic system cancer	0.000178	0.000967	CcSEcCtD
Sparfloxacin—Nausea—Bleomycin—lymphatic system cancer	0.000177	0.000961	CcSEcCtD
Sparfloxacin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000176	0.000957	CcSEcCtD
Sparfloxacin—Asthenia—Mitoxantrone—lymphatic system cancer	0.000173	0.000942	CcSEcCtD
Sparfloxacin—Dizziness—Carmustine—lymphatic system cancer	0.000172	0.000934	CcSEcCtD
Sparfloxacin—Haemoglobin—Methotrexate—lymphatic system cancer	0.00017	0.000926	CcSEcCtD
Sparfloxacin—Diarrhoea—Vincristine—lymphatic system cancer	0.00017	0.000923	CcSEcCtD
Sparfloxacin—Haemorrhage—Methotrexate—lymphatic system cancer	0.000169	0.000921	CcSEcCtD
Sparfloxacin—Hepatitis—Methotrexate—lymphatic system cancer	0.000169	0.000921	CcSEcCtD
Sparfloxacin—Pharyngitis—Methotrexate—lymphatic system cancer	0.000168	0.000914	CcSEcCtD
Sparfloxacin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000165	0.000899	CcSEcCtD
Sparfloxacin—Vomiting—Carmustine—lymphatic system cancer	0.000165	0.000898	CcSEcCtD
Sparfloxacin—Dizziness—Vincristine—lymphatic system cancer	0.000164	0.000892	CcSEcCtD
Sparfloxacin—Rash—Carmustine—lymphatic system cancer	0.000164	0.000891	CcSEcCtD
Sparfloxacin—Dermatitis—Carmustine—lymphatic system cancer	0.000164	0.00089	CcSEcCtD
Sparfloxacin—Headache—Carmustine—lymphatic system cancer	0.000163	0.000885	CcSEcCtD
Sparfloxacin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00016	0.000871	CcSEcCtD
Sparfloxacin—Tinnitus—Methotrexate—lymphatic system cancer	0.000158	0.000859	CcSEcCtD
Sparfloxacin—Vomiting—Vincristine—lymphatic system cancer	0.000158	0.000857	CcSEcCtD
Sparfloxacin—Rash—Vincristine—lymphatic system cancer	0.000156	0.00085	CcSEcCtD
Sparfloxacin—Dermatitis—Vincristine—lymphatic system cancer	0.000156	0.00085	CcSEcCtD
Sparfloxacin—Headache—Vincristine—lymphatic system cancer	0.000155	0.000845	CcSEcCtD
Sparfloxacin—Nausea—Carmustine—lymphatic system cancer	0.000154	0.000839	CcSEcCtD
Sparfloxacin—Vomiting—Mitoxantrone—lymphatic system cancer	0.000153	0.000835	CcSEcCtD
Sparfloxacin—Rash—Mitoxantrone—lymphatic system cancer	0.000152	0.000828	CcSEcCtD
Sparfloxacin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000152	0.000827	CcSEcCtD
Sparfloxacin—Chills—Methotrexate—lymphatic system cancer	0.000152	0.000826	CcSEcCtD
Sparfloxacin—Headache—Mitoxantrone—lymphatic system cancer	0.000151	0.000823	CcSEcCtD
Sparfloxacin—Alopecia—Methotrexate—lymphatic system cancer	0.00015	0.000814	CcSEcCtD
Sparfloxacin—Nausea—Vincristine—lymphatic system cancer	0.000147	0.000801	CcSEcCtD
Sparfloxacin—Dysgeusia—Methotrexate—lymphatic system cancer	0.000144	0.000785	CcSEcCtD
Sparfloxacin—Nausea—Mitoxantrone—lymphatic system cancer	0.000143	0.00078	CcSEcCtD
Sparfloxacin—Back pain—Methotrexate—lymphatic system cancer	0.000143	0.000776	CcSEcCtD
Sparfloxacin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000137	0.000744	CcSEcCtD
Sparfloxacin—Malaise—Methotrexate—lymphatic system cancer	0.000133	0.000723	CcSEcCtD
Sparfloxacin—Vertigo—Methotrexate—lymphatic system cancer	0.000132	0.00072	CcSEcCtD
Sparfloxacin—Cough—Methotrexate—lymphatic system cancer	0.000129	0.0007	CcSEcCtD
Sparfloxacin—Convulsion—Methotrexate—lymphatic system cancer	0.000128	0.000695	CcSEcCtD
Sparfloxacin—Myalgia—Methotrexate—lymphatic system cancer	0.000125	0.000683	CcSEcCtD
Sparfloxacin—Chest pain—Methotrexate—lymphatic system cancer	0.000125	0.000683	CcSEcCtD
Sparfloxacin—Arthralgia—Methotrexate—lymphatic system cancer	0.000125	0.000683	CcSEcCtD
Sparfloxacin—Discomfort—Methotrexate—lymphatic system cancer	0.000124	0.000674	CcSEcCtD
Sparfloxacin—Confusional state—Methotrexate—lymphatic system cancer	0.000121	0.00066	CcSEcCtD
Sparfloxacin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00012	0.000654	CcSEcCtD
Sparfloxacin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000118	0.000641	CcSEcCtD
Sparfloxacin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000116	0.000633	CcSEcCtD
Sparfloxacin—Anorexia—Methotrexate—lymphatic system cancer	0.000115	0.000624	CcSEcCtD
Sparfloxacin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00011	0.000596	CcSEcCtD
Sparfloxacin—Insomnia—Methotrexate—lymphatic system cancer	0.000109	0.000592	CcSEcCtD
Sparfloxacin—Paraesthesia—Methotrexate—lymphatic system cancer	0.000108	0.000588	CcSEcCtD
Sparfloxacin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000107	0.000583	CcSEcCtD
Sparfloxacin—Somnolence—Methotrexate—lymphatic system cancer	0.000107	0.000582	CcSEcCtD
Sparfloxacin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000106	0.000576	CcSEcCtD
Sparfloxacin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000105	0.000569	CcSEcCtD
Sparfloxacin—Pain—Methotrexate—lymphatic system cancer	0.000103	0.00056	CcSEcCtD
Sparfloxacin—Feeling abnormal—Methotrexate—lymphatic system cancer	9.91e-05	0.000539	CcSEcCtD
Sparfloxacin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	9.83e-05	0.000535	CcSEcCtD
Sparfloxacin—Urticaria—Methotrexate—lymphatic system cancer	9.55e-05	0.00052	CcSEcCtD
Sparfloxacin—Abdominal pain—Methotrexate—lymphatic system cancer	9.51e-05	0.000517	CcSEcCtD
Sparfloxacin—Body temperature increased—Methotrexate—lymphatic system cancer	9.51e-05	0.000517	CcSEcCtD
Sparfloxacin—Hypersensitivity—Methotrexate—lymphatic system cancer	8.86e-05	0.000482	CcSEcCtD
Sparfloxacin—Asthenia—Methotrexate—lymphatic system cancer	8.63e-05	0.000469	CcSEcCtD
Sparfloxacin—Pruritus—Methotrexate—lymphatic system cancer	8.51e-05	0.000463	CcSEcCtD
Sparfloxacin—Diarrhoea—Methotrexate—lymphatic system cancer	8.23e-05	0.000448	CcSEcCtD
Sparfloxacin—Dizziness—Methotrexate—lymphatic system cancer	7.95e-05	0.000433	CcSEcCtD
Sparfloxacin—Vomiting—Methotrexate—lymphatic system cancer	7.65e-05	0.000416	CcSEcCtD
Sparfloxacin—Rash—Methotrexate—lymphatic system cancer	7.58e-05	0.000413	CcSEcCtD
Sparfloxacin—Dermatitis—Methotrexate—lymphatic system cancer	7.58e-05	0.000412	CcSEcCtD
Sparfloxacin—Headache—Methotrexate—lymphatic system cancer	7.53e-05	0.00041	CcSEcCtD
Sparfloxacin—Nausea—Methotrexate—lymphatic system cancer	7.14e-05	0.000389	CcSEcCtD
